High fat diets and pathology in the guinea pig. Atherosclerosis or liver damage?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 2, 2013, Pages 355-364

  Ye, Peng ^a   Cheah, Irwin K ^a   Halliwell, Barry ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Atherosclerosis; Cholesterol; Dietary supplementation; Guinea pig; Non alcoholic fatty liver disease

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CARDIOVASCULAR AGENT; FLAVONOID; HYDROXYCITRIC ACID; INULA RACEMOSA EXTRACT; PLANT EXTRACT; POLYPHENOL; SIMVASTATIN; SITOSTANOL; UNCLASSIFIED DRUG; VARESPLADIB; XANTHOPHYLL;

ATHEROSCLEROSIS; CHOLESTEROL INTAKE; DIET SUPPLEMENTATION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG MECHANISM; FAT INTAKE; GUINEA PIG; HUMAN; LIPID DIET; LIVER INJURY; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

ANIMALS; ATHEROSCLEROSIS; DIETARY FATS; GUINEA PIGS; LIVER; MODELS, ANIMAL;

ANIMALIA; CAVIA;

EID: 84871732223     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.11.008     Document Type: Review

References (138)

1. O'Donnell C.J., Nabel E.G. Genomics of cardiovascular disease. N. Engl. J. Med. 2011, 365:2098-2109.
2. Nabel E.G., Braunwald E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 2012, 366:54-63.
3. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
4. Napoli C., D'Armiento F.P., Mancini F.P., Postiglione A., Witztum J.L., Palumbo G., Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia-intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 1997, 100:2680-2690.
5. Pesonen E. Preliminary and early stages of atherosclerosis in childhood. Zentralbl. Allg. Pathol. 1989, 135:545-548.
6. Hong Y.M. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ. J. 2010, 40:1-9.
7. Dillard A., Matthan N.R., Lichtenstein A.H. Use of hamster as a model to study diet-induced atherosclerosis. Nutr. Metab. 2010, 7:89.
8. Yanni A.E. The laboratory rabbit: an animal model of atherosclerosis research. Lab. Anim. 2004, 38:246-256.
9. Fernandez M.L., Volek J.S. Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr. Metab. 2006, 3:17.
10. Fernandez M.L., Wilson T.A., Conde K., Vergara-Jimenez M., Nicolosi R.J. Hamsters and guinea pigs differ in their plasma lipoprotein cholesterol distribution when fed diets varying in animal protein, soluble fiber, or cholesterol content. J. Nutr. 1999, 129:1323-1332.
11. Kritchevsky D. Dietary protein, cholesterol and atherosclerosis: a review of the early history. J. Nutr. 1995, 125:589S-593S.
12. Cook R.P., Thomson R.O. Cholesterol metabolism. 3. Cholesterol metabolism in the guinea pig and rabbit. Biochem. J. 1951, 49:72-77.
13. Sharman M.J., Fernandez M.L., Zern T.L., Torres-Gonzalez M., Kraemer W.J., Volek J.S. Replacing dietary carbohydrate with protein and fat decreases the concentrations of small LDL and the inflammatory response induced by atherogenic diets in the guinea pig. J. Nutr. Biochem. 2008, 19:732-738.
14. Mangathayaru K., Kuruvilla S., Balakrishna K., Venkhatesh J. Modulatory effect of Inula racemosa Hook. f. (Asteraceae) on experimental atherosclerosis in guinea-pigs. J. Pharm. Pharmacol. 2009, 61:1111-1118.
15. Amran A.A., Zaiton Z., Faizah O., Morat P. Effects of Garcinia atroviridis on serum profiles and atherosclerotic lesions in the aorta of guinea pigs fed a high cholesterol diet. Singapore Med. J. 2009, 50:295-299.
16. Sable-Amplis R., Sicart R. Relationship between aorta cholesterol content and plasma lipids in guinea pigs fed an atherogenic diet. Atherosclerosis 1983, 48:295-299.
17. Tararak E.M. Regression of experimental atherosclerosis of the aorta in guinea pigs. Bull. Exp. Biol. Med. 1968, 67:118-121.
18. Bernick S., Patek P.R., Ershoff B.H., Wells A. Effect of cholesterol feeding on the thyroid gland and vascular structures of the rabbit, guinea pig, hamster and rat. Am. J. Pathol. 1962, 41:661-677.
19. Rice B.H., Kraft J., Destaillats F., Bauman D.E., Lock A.L. Ruminant-produced trans-fatty acids raise plasma total and small HDL particle concentrations in male Hartley guinea pigs. J. Nutr. 2010, 140:2173-2179.
20. Puppione D.L., Sardet C., Yamanaka W., Ostwald R., Nichols A.V. Plasma lipoproteins of cholesterol-fed guinea pigs. Biochim. Biophys. Acta 1971, 231:295-301.
21. Torres-Gonzalez M., Volek J.S., Sharman M., Contois J.H., Fernandez M.L. Dietary carbohydrate and cholesterol influence the number of particles and distributions of lipoprotein subfractions in guinea pigs. J. Nutr. Biochem. 2006, 17:773-779.
22. Nakashima Y., Wight T.N., Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc. Res. 2008, 79:14-23.
23. Lynch S.M., Gaziano J.M., Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Subcell. Biochem. 1996, 25:331-367.
24. Singh V., Tiwari R.L., Dikshit M., Barthwal M.K. Models to study atherosclerosis: a mechanistic insight. Curr. Vasc. Pharmacol. 2009, 7:75-109.
25. Erbel R., Budoff M. Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure. Eur. Heart J. 2012, 33:1201-1213.
26. Qiang B.P., Toma J., Fujii H., Osherov A.B., Nili N., Sparkes J.D., Fefer P., Samuel M., Butany J., Leong-Poi H., Strauss B.H. Statin therapy prevents expansive remodeling in venous bypass grafts. Atherosclerosis 2012, 223:106-113.
27. Yazdani S.K., Otsuka F., Nakano M., Finn A.V., Virmani R. Do animal models of vein graft atherosclerosis predict outcomes in man?. Atherosclerosis 2012, 223:102-105.
28. Tararak E.M. Regression of experimental atherosclerosis of aorta in guinea pigs. Bull. Exp. Biol. Med.-USSR 1969, 67:211.
29. Malinow M.R. Experimental-models of atherosclerosis regression. Atherosclerosis 1983, 48:105-118.
30. Reilly S.D., Litovsky S.H., Steinkampf M.P., Caulfield J.B. Statins improve human coronary atherosclerotic plaque morphology. Tex. Heart Inst. J. 2008, 35:99-103.
31. Leite J.O., DeOgburn R., Ratliff J., Su R., Smyth J.A., Volek J.S., McGrane M.M., Dardik A., Fernandez M.L. Low-carbohydrate diets reduce lipid accumulation and arterial inflammation in guinea pigs fed a high-cholesterol diet. Atherosclerosis 2010, 209:442-448.
32. Krieglstein J., Kewitz T., Kirchhefer U., Hofnagel O., Weissen-Plenz G., Reinbold M., Klumpp S. Damage of guinea pig heart and arteries by a trioleate-enriched diet and of cultured cardiomyocytes by oleic acid. PLoS One 2010, 5:e9561.
33. Cos E., Ramjiganesh T., Roy S., Yoganathan S., Nicolosi R.J., Fernandez M.L. Soluble fiber and soybean protein reduce atherosclerotic lesions in guinea pigs. Sex and hormonal status determine lesion extension. Lipids 2001, 36:1209-1216.
34. Leite J.O., Vaishnav U., Puglisi M., Fraser H., Trias J., Fernandez M.L. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc. Disord. 2009, 9:7.
35. Qiao Y., Yokoyama M., Kameyama K., Asano G. Effect of vitamin E on vascular integrity in cholesterol-fed guinea pigs. Arterioscler. Thromb. 1993, 13:1885-1892.
36. Zern T.L., West K.L., Fernandez M.L. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J. Nutr. 2003, 133:2268-2272.
37. Kim J.E., Leite J.O., DeOgburn R., Smyth J.A., Clark R.M., Fernandez M.L. A lutein-enriched diet prevents cholesterol accumulation and decreases oxidized LDL and inflammatory cytokines in the aorta of guinea pigs. J. Nutr. 2011, 141:1458-1463.
38. Halliwell B., Gutteridge J. Free Radicals in Biology and Medicine 2007, Oxford University Press, London. 4 ed.
39. Aw T.Y. Determinants of intestinal detoxication of lipid hydroperoxides. Free Radic. Res. 1998, 28:637-646.
40. Staprans I., Pan X.M., Rapp J.H., Feingold K.R. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis. Mol. Nutr. Food Res. 2005, 49:1075-1082.
41. Kroger K., Suckel A., Hirche H., Rudofsky G. Different prevalence of asymptomatic atherosclerotic lesions in males and females. Vasc. Med. 1999, 4:61-65.
42. Maxwell S.R.J. Women and heart disease. Basic Res. Cardiol. 1998, 93:79-84.
43. Witteman J.C., Grobbee D.E., Kok F.J., Hofman A., Valkenburg H.A. Increased risk of atherosclerosis in women after the menopause. BMJ 1989, 298:642-644.
44. Clarkson T.B., Anthony M.S., Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab. 2001, 86:41-47.
45. Luz Fernandez M., West K.L., Roy S., Ramjiganesh T. Dietary fat saturation and gender/hormonal status modulate plasma lipids and lipoprotein composition. J. Nutr. Biochem. 2001, 12:703-710.
46. Fernandez M.L., Sun D.M., Tosca M.A., McNamara D.J. Citrus pectin and cholesterol interact to regulate hepatic cholesterol homeostasis and lipoprotein metabolism: a dose-response study in guinea pigs. Am. J. Clin. Nutr. 1994, 59:869-878.
47. Fernandez M.L., Sun D.M., Tosca M., McNamara D.J. Guar gum effects on plasma low-density lipoprotein and hepatic cholesterol metabolism in guinea pigs fed low- and high-cholesterol diets: a dose-response study. Am. J. Clin. Nutr. 1995, 61:127-134.
48. Fernandez M.L., Ruiz L.R., Conde A.K., Sun D.M., Erickson S.K., McNamara D.J. Psyllium reduces plasma LDL in guinea pigs by altering hepatic cholesterol homeostasis. J. Lipid Res. 1995, 36:1128-1138.
49. Fernandez M.L., Vergara-Jimenez M., Romero A.L., Erickson S.K., McNamara D.J. Gender differences in response to dietary soluble fiber in guinea pigs: effects of pectin, guar gum, and psyllium. J. Lipid Res. 1995, 36:2191-2202.
50. Robinson J.G., Fox K.M., Bullano M.F., Grandy S., Grp S.S. Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovasc. Disord. 2009, 9:46.
51. Howard G., Manolio T.A., Burke G.L., Wolfson S.K., OLeary D.H. Does the association of risk factors and atherosclerosis change with age?-an analysis of the combined ARIC and CHS cohorts. Stroke 1997, 28:1693-1701.
52. Jackson J.R., Ryan M.J., Hao Y., Alway S.E. Mediation of endogenous antioxidant enzymes and apoptotic signaling by resveratrol following muscle disuse in the gastrocnemius muscles of young and old rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R1572-R1581.
53. McLean A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 2004, 56:163-184.
54. Ungvari Z., Kaley G., de Cabo R., Sonntag W.E., Csiszar A. Mechanisms of vascular aging: new perspectives. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65:1028-1041.
55. Shen H., He L., Price R.L., Fernandez M.L. Dietary soluble fiber lowers plasma LDL cholesterol concentrations by altering lipoprotein metabolism in female guinea pigs. J. Nutr. 1998, 128:1434-1441.
56. Abdel-Fattah G., Fernandez M.L., McNamara D.J. Regulation of very low density lipoprotein apo B metabolism by dietary fat saturation and chain length in the guinea pig. Lipids 1998, 33:23-31.
57. Fernandez M.L., Soscia A.E., Sun G.S., Tosca M., McNamara D.J., McDonald B.E. Olive oil and rapeseed oil differ in their effect on plasma low-density lipoprotein metabolism in the guinea-pig. Br. J. Nutr. 1996, 76:869-880.
58. Fernandez M.L., Vergara-Jimenez M., Conde K., Abdel-Fattah G. Dietary carbohydrate type and fat amount alter VLDL and LDL metabolism in guinea pigs. J. Nutr. 1996, 126:2494-2504.
59. Fernandez M.L., Conde A.K., Ruiz L.R., Montano C., Ebner J., McNamara D.J. Carbohydrate type and amount alter intravascular processing and catabolism of plasma lipoproteins in guinea pigs. Lipids 1995, 30:619-626.
60. Lin E.C., Fernandez M.L., McNamara D.J. High density lipoprotein metabolism is altered by dietary cholesterol but not fat saturation in guinea pigs. Atherosclerosis 1995, 112:161-175.
61. Fernandez M.L., Abdel-Fattah G., McNamara D.J. Dietary fat saturation modifies the metabolism of LDL subfractions in guinea pigs. Arterioscler. Thromb. 1993, 13:1418-1428.
62. Abdel-Fattah G., Fernandez M.L., McNamara D.J. Regulation of guinea pig very low density lipoprotein secretion rates by dietary fat saturation. J. Lipid Res. 1995, 36:1188-1198.
63. Ibrahim J.B., McNamara D.J. Cholesterol homeostasis in guinea pigs fed saturated and polyunsaturated fat diets. Biochim. Biophys. Acta 1988, 963:109-118.
64. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol-modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320:915-924.
65. Witztum J.L., Steinberg D. Role of oxidized low-density-lipoprotein in atherogenesis. J. Clin. Invest. 1991, 88:1785-1792.
66. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 1996, 34:599-608.
67. Frei B. Cardiovascular-disease and nutrient antioxidants-role of low-density-lipoprotein oxidation. Crit. Rev. Food Sci. Nutr. 1995, 35:83-98.
68. Liu L.K., Lee H.J., Shih Y.W., Cuiyau C.C., Wang C.J. Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. J. Food Sci. 2008, 73:H113-H121.
69. Naderi G.A., Asgary S., Sarraf-Zadegan N., Shirvany H. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol. Cell. Biochem. 2003, 246:193-196.
70. Chatterjee I.B. Evolution and the biosynthesis of ascorbic acid. Science 1973, 182:1271-1272.
71. Wright H.P., Evans M., Green R.P. Aortic endothelial mitosis and Evans blue uptake in cholesterol-fed subscorbutic guinea-pigs. Atherosclerosis 1975, 21:105-113.
72. Cyrus T., Yao Y., Rokach J., Tang L.X., Pratico D. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation 2003, 107:521-523.
73. Thomas S.R., Leichtweis S.B., Pettersson K., Croft K.D., Mori T.A., Brown A.J., Stocker R. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21:585-593.
74. Wilson R.B., Middleton C.C., Sun G.Y. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J. Nutr. 1978, 108:1858-1867.
75. Hodis H.N., Mack W.J., LaBree L., Mahrer P.R., Sevanian A., Liu C.R., Liu C.H., Hwang J., Selzer R.H., Azen S.P. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 2002, 106:1453-1459.
76. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001, 103:919-925.
77. Micheletta F., Natoli S., Misuraca M., Sbarigia E., Diczfalusy U., Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque. Arterioscler. Thromb. Vasc. Biol. 2004, 24:136-140.
78. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch. Biochem. Biophys. 2008, 476:107-112.
79. Auclair S., Silberberg M., Gueux E., Morand C., Mazur A., Milenkovic D., Scalbert A. Apple polyphenols and fibers attenuate atherosclerosis in apolipoprotein E-deficient mice. J. Agric. Food Chem. 2008, 56:5558-5563.
80. Katsuda S., Suzuki K., Koyama N., Takahashi M., Miyake M., Hazama A., Takazawa K. Safflower seed polyphenols (N-(p-coumaroyl)serotonin and N-feruloylserotonin) ameliorate atherosclerosis and distensibility of the aortic wall in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits. Hypertens. Res. 2009, 32:944-949.
81. Loke W.M., Proudfoot J.M., Hodgson J.M., McKinley A.J., Hime N., Magat M., Stocker R., Croft K.D. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2010, 30:749-757.
82. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
83. Fuhrman B., Volkova N., Coleman R., Aviram M. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J. Nutr. 2005, 135:722-728.
84. Dwyer J.H., Navab M., Dwyer K.M., Hassan K., Sun P., Shircore A., Hama-Levy S., Hough G., Wang X., Drake T., Merz C.N., Fogelman A.M. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation 2001, 103:2922-2927.
85. Roy S., Vega-Lopez S., Fernandez M.L. Gender and hormonal status affect the hypolipidemic mechanisms of dietary soluble fiber in guinea pigs. J. Nutr. 2000, 130:600-607.
86. Bea F., Blessing E., Bennett B., Levitz M., Wallace E.P., Rosenfeld M.E. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1832-1837.
87. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
88. Kumai T., Oonuma S., Matsumoto N., Takeba Y., Taniguchi R., Kamio K., Miyazu O., Koitabashi Y., Sekine S., Tadokoro M., Kobayashi S. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci. 2004, 74:2129-2142.
89. Sezer E.D., Sozmen E.Y., Nart D., Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc. Health Risk Manag. 2011, 7:333-343.
90. Madsen C.S., Janovitz E., Zhang R., Nguyen-Tran V., Ryan C.S., Yin X., Monshizadegan H., Chang M., D'Arienzo C., Scheer S., Setters R., Search D., Chen X., Zhuang S., Kunselman L., Peters A., Harrity T., Apedo A., Huang C., Cuff C.A., Kowala M.C., Blanar M.A., Sun C.Q., Robl J.A., Stein P.D. The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J. Pharmacol. Exp. Ther. 2008, 324:576-586.
91. Conde K., Vergara-Jimenez M., Krause B.R., Newton R.S., Fernandez M.L. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J. Lipid Res. 1996, 37:2372-2382.
92. Conde K., Pineda G., Newton R.S., Fernandez M.L. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Biochem. Pharmacol. 1999, 58:1209-1219.
93. Kolovou G.D., Katerina A., Ioannis V., Cokkinos D.V. Simvastatin: two decades in a circle. Cardiovasc. Ther. 2008, 26:166-178.
94. Doggrell S.A. Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Rev. Recent Clin. Trials 2006, 1:143-153.
95. Ramjiganesh T., Roy S., McIntyre J.C., Luz Fernandez M. The hypocholesterolaemic effects of sitostanol in the guinea pig are in part related to changes in hepatic lipids and lipoprotein composition. Br. J. Nutr. 2001, 85:165-172.
96. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA 2003, 289:1681-1690.
97. Madsen C.S., Janovitz E., Zhang R., Nguyen-Tran V., Ryan C.S., Yin X.H., Monshizadegan H., Chang M., D'Arienzo C., Scheer S., Setters R., Search D., Chen X., Zhuang S.B., Kunselman L., Peters A., Harrity T., Apedo A., Huang C., Cuff C.A., Kowala M.C., Blanar M.A., Sun C.Q., Robl J.A., Stein P.D. The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J. Pharmacol. Exp. Ther. 2008, 324:576-586.
98. Aggarwal D., West K.L., Zern T.L., Shrestha S., Vergara-Jimenez M., Fernandez M.L. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc. Disord. 2005, 5:30.
99. Caslake M.J., Packard C.J. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr. Opin. Lipidol. 2003, 14:347-352.
100. Rosenson R.S., Elliott M., Stasiv Y., Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur. Heart J. 2011, 32:999-1005.
101. Dietschy J.M., Wilson J.D. Regulation of cholesterol metabolism. 3. N. Engl. J. Med. 1970, 282:1241-1249.
102. Lin E.C., Fernandez M.L., Tosca M.A., McNamara D.J. Regulation of hepatic LDL metabolism in the guinea pig by dietary fat and cholesterol. J. Lipid Res. 1994, 35:446-457.
103. Ostwald R., Yamanaka W., Light M., Kroes J. The time course of metabolic changes induced by dietary cholesterol in guinea pigs. Atherosclerosis 1977, 26:41-53.
104. Beck B.I., Drevon C.A. Influence of cholesterol and fat feeding on hepatic lysosomal enzymes in guinea pigs. J. Nutr. 1980, 110:1935-1939.
105. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363:1341-1350.
106. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
107. Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2012, 35:1135-1144.
108. Anstee Q.M., Daly A.K., Day C.P. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta 2011, 1812:1557-1566.
109. Enjoji M., Nakamuta M. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?. World J. Gastroenterol. 2010, 16:800-803.
110. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52:59-69.
111. Malhi H., Gores G.J., Lemasters J.J. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 2006, 43:S31-S44.
112. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S20-S27.
113. Yasutake K., Nakamuta M., Shima Y., Ohyama A., Masuda K., Haruta N., Fujino T., Aoyagi Y., Fukuizumi K., Yoshimoto T., Takemoto R., Miyahara T., Harada N., Hayata F., Nakashima M., Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand. J. Gastroenterol. 2009, 44:471-477.
114. Enjoji M., Machida K., Kohjima M., Kato M., Kotoh K., Matsunaga K., Nakashima M., Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 2010, 9:29.
115. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
116. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
117. Higuchi N., Kato M., Shundo Y., Tajiri H., Tanaka M., Yamashita N., Kohjima M., Kotoh K., Nakamuta M., Takayanagi R., Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 2008, 38:1122-1129.
118. Nakamuta M., Fujino T., Yada R., Yada M., Yasutake K., Yoshimoto T., Harada N., Higuchi N., Kato M., Kohjima M., Taketomi A., Maehara Y., Nakashima M., Kotoh K., Enjoji M. Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. Int. J. Mol. Med. 2009, 23:603-608.
119. Fan C.Y., Pan J., Chu R., Lee D., Kluckman K.D., Usuda N., Singh I., Yeldandi A.V., Rao M.S., Maeda N., Reddy J.K. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J. Biol. Chem. 1996, 271:24698-24710.
120. Xu Z., Chen L., Leung L., Yen T.S., Lee C., Chan J.Y. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4120-4125.
121. Lu S.C., Alvarez L., Huang Z.Z., Chen L., An W., Corrales F.J., Avila M.A., Kanel G., Mato J.M. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5560-5565.
122. Watanabe S., Horie Y., Suzuki A. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 2005, 33:161-166.
123. Brix A.E., Elgavish A., Nagy T.R., Gower B.A., Rhead W.J., Wood P.A. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse. Mol. Genet. Metab. 2002, 75:219-226.
124. Wortham M., He L., Gyamfi M., Copple B.L., Wan Y.J. The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 2008, 53:2761-2774.
125. Fan J.G., Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 2009, 8:233-240.
126. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87:1-16.
127. Lieber C.S., Leo M.A., Mak K.M., Xu Y., Cao Q., Ren C., Ponomarenko A., DeCarli L.M. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 2004, 79:502-509.
128. Zou Y., Li J., Lu C., Wang J., Ge J., Huang Y., Zhang L., Wang Y. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci. 2006, 79:1100-1107.
129. Schwemmer M., Sommer O., Koeckerbauer R., Bassenge E. Cardiovascular dysfunction in hypercholesterolemia associated with enhanced formation of AT1-receptor and of eicosanoids. J. Cardiovasc. Pharmacol. Ther. 2000, 5:59-68.
130. deOgburn R., Leite J.O., Ratliff J., Volek J.S., McGrane M.M., Fernandez M.L. Effects of increased dietary cholesterol with carbohydrate restriction on hepatic lipid metabolism in Guinea pigs. Comp. Med. 2012, 62:109-115.
131. Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin. Sci. (Lond.) 2008, 115:1-12.
132. Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur. Heart J. 2012, 33:1190-1200.
133. Scorletti E., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011, 40:332-343.
134. Padilla-Carlin D.J., McMurray D.N., Hickey A.J. The guinea pig as a model of infectious diseases. Comp. Med. 2008, 58:324-340.
135. Cardiovascular disease, in: Media centre fact sheets, World Health Organization, 2011.
136. Ramjiganesh T., Roy S., Nicolosi R.J., Young T.L., McIntyre J.C., Fernandez M.L. Corn husk oil lowers plasma LDL cholesterol concentrations by decreasing cholesterol absorption and altering hepatic cholesterol metabolism in guinea pigs. J. Nutr. Biochem. 2000, 11:358-366.
137. Flynn T.T., Kubena K.S., Rhee K.S. Modification of plasma and hepatic lipids of guinea pigs by feeding high oleic acid pork compared with regular pork. J. Nutr. 1992, 122:1855-1861.
138. 2 in adult guinea pigs. J. Nutr. 2002, 132:1149-1152.